Recommendation 2

Neurodevelopmental investigations should automatically be part of the PregPV initiatives for a medication where one or more apply: i) It is mechanistically plausible for the medication to be associated with an increased risk or it belongs to a class of medications where effects have been observed (e.g., central nervous system acting medications) ii) There is evidence (preclinical or human data) of a higher risk to physical development (e.g., structural anomalies) iii) There is evidence (preclinical or human data) of a higher risk to brain development iv) The medication is likely to be widely used among women of childbearing potential